De Stefano R, Frati E, Senesi M, Selvi E, Vassalli D, Marcolongo R
Istituto di Reumatologia, Università, Siena.
Recenti Prog Med. 1992 Sep;83(9):510-4.
The authors have evaluated the effects of long-term treatment of digital vasculitis secondary to various types of connective tissue disease, Systemic Lupus Erythematosus (SLE), Progressive Systemic Sclerosis (PSS), Sjögren's Syndrome (SS), using iloprost. The drug has proven to be effective both in reducing pain and clinical symptoms induced by vasospastic phenomena, as well as in promoting the healing of serious acral ischemic lesions. In the patient with LES, clinical modifications of the local vasculitic phenomena have been associated with a contemporaneous remission of the disease. The persistence of the drug's clinical effects even after suspension of treatment, instrumental and biohumoral changes and concomitant systemic effects on the disease lead to the conclusion that the drug's effect, is not merely due its vasodilating action and its ability to interfere with the coagulative process, but rather must be sought within the context of a morpho-structural repair of the microcirculation.
作者评估了伊洛前列素对各种类型结缔组织病继发的指端血管炎的长期治疗效果，这些结缔组织病包括系统性红斑狼疮（SLE）、进行性系统性硬化症（PSS）、干燥综合征（SS）。事实证明，该药物在减轻血管痉挛现象引起的疼痛和临床症状方面有效，同时在促进严重的肢端缺血性病变愈合方面也有效。在患有SLE的患者中，局部血管炎现象的临床改善与疾病的同期缓解相关。即使在停药后，该药物的临床效果仍持续存在，仪器检查和生物体液变化以及对疾病的伴随全身作用得出这样的结论：该药物的作用不仅仅归因于其血管舒张作用及其干扰凝血过程的能力，而更必须在微循环的形态结构修复的背景下寻找原因。
